Novartis

According to GlobalData’s report, oncology remains the leading therapeutic area in Q1 2025, with most of the deals targeting…

Chakravarthi AVPS delivers special address on drug safety and moderates key discussion at PHARMAP 2025, shaping the future of…

The revival of CNS drug development is being fueled by advancements in neuroimmunology and neurodegeneration, moving beyond…

GlobalData analyst consensus forecast predicts the global revenue of Pluvicto to rise from $980 million in 2023 to $4.3 billion by…

Fabhalta specifically targets the alternative complement pathway of the immune system. When overly activated in the kidneys, the…

Merck, Biogen, and Novartis lead major transactions In May 2024, the pharmaceutical industry strategically pursued key…

As India transitions to become the drug development BPO of the world, MNC pharma sharpens focus on next-generation cures and…

On the financial details of the agreements, JB Pharma said it will pay USD 116 million (Rs 964 crore), excluding applicable taxes,…

Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two…

The US President Joe Biden in August signed into law the Inflation Reduction Act (IRA), which allows the federal Medicare scheme…